Form D · Biotechnology
Vitls Inc.
Houston, TX · CIK 0001749947
Offering snapshot reported Nov 29, 2022 · SEC filing
- Reported sold
- $1.31M Offering amount: $2M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2022 | Initial | $1,311,301 | No comparison | 9 | SEC filing |
| Nov 12, 2021 | Initial | $4,475,212 | No comparison | 24 | SEC filing |
| Dec 18, 2018 | Initial | $385,000 | No comparison | 7 | SEC filing |
| Aug 13, 2018 | Initial | $1,065,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-465994
Source: Form D, filed Nov 29, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Greg Campbell | Director |
| Cadell Liedtke | Director |
| Gregory Moss | Director |
| Greg Moss | Director |
| Werner Vorster | Director, Executive |
| Louise Vorster | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2450 Holcombe Blvd., Suite X+210 C/O Tmcx Med Centre Innovation Institute
Houston, TX, 77021
Houston, TX, 77021